IL22 and metabolic disease: Fatkhullina et al. (2018) proposed that IL-23 and its downstream target IL-22 repressed AS by inhibiting pro-atherogenic microbiota and microbial metabolites such as TMAO. IL-22 is a characteristic cytokine of Th17 myriad and IL-23 controls the function of Th17 subsets (Buonocore et al., 2010; Peshkova et al., 2016). Though Wang et al. revealed that IL-22 and TH17 pathway could alleviate metabolic disorders in diabetes (Wang et al., 2014), the role of IL-22 and IL-23 in AS remains to be determined.